INTERIM REPORT JANUARY-MARCH 2007

INTERIM REPORT JANUARY-MARCH 2007

•	The Group's revenues from sales of goods and royalties amounted to 300.3
(282.2) MSEK, an increase of 6 percent.

•	Growth within the Esthetics product area was 15 percent and revenues amounted
to 239.9 (208.0) MSEK.

•	Operating income amounted to 56.1 (56.0) MSEK.

•	Net income after tax amounted to 41.7 (39.0) MSEK.

•	Earnings per share after full dilution were 0.42 (0.39) kr.

•	Collaboration agreement with Medy-Tox Inc. regarding the development and
commercialization of botulinum toxin products.

•	Exclusive distribution agreement with Medy-Tox Inc. regarding Medy-Tox's
botulinum toxin type A product for Europe, as well as a non-exclusive agreement
to sell the product in Japan.

•	On May 2, 2007 RESTYLANE Perlane was approved for sales in the USA.


Queries should be addressed to:

Erika Kjellberg Eriksson, Vice President and CFO
Tel: +46 (0)70-974 9020
Madelene Sandgren, Director Investor Relations and Corporate Communications
Tel: +46 (0)70-974 9015

Q-Med AB is a rapidly growing and profitable biotechnology/medical device
company. The company develops, manufactures, markets and sells primarily medical
implants. The majority of the products are based on the company's patented
technology, NASHA™ for the production of stabilized non-animal hyaluronic acid. 
The product portfolio today contains: RESTYLANE for the filling out of lips and
facial wrinkles and for facial contouring, DUROLANE, for the treatment of
osteoarthritis of the hip and knee joints, DEFLUX for the treatment of
vesicoureteral reflux, VUR, (a malformation of the urinary bladder) in children,
ZUIDEX, for the treatment of stress urinary incontinence in women and SOLESTA,
for the treatment of fecal incontinence. Sales are made through the company's
own subsidiaries or distributors in over 70 countries. Q-Med today has just over
600 co-workers, with approximately 400 at the company's head office and
production facility in Uppsala, Sweden. Q-Med AB is listed in the Large Cap
segment of the OMX Nordic Stock Exchange in Stockholm.

NASHA, DUROLANE, SOLESTA, ZUIDEX, IMPLACER, DEFLUX and all product names within
the RESTYLANE family are trademarks that belong to Q-Med AB.